Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.474 EUR -1.86% Market Closed
Market Cap: 135.8m EUR

Intrinsic Value

IPH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IPH stock under the Base Case scenario is 4.719 EUR. Compared to the current market price of 1.474 EUR, Innate Pharma SA is Undervalued by 69%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPH Intrinsic Value
4.719 EUR
Undervaluation 69%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Innate Pharma SA

What is Valuation History?
Compare IPH to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about IPH?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Innate Pharma SA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Innate Pharma SA

Current Assets 85.7m
Cash & Short-Term Investments 80.8m
Receivables 5m
Non-Current Assets 25.3m
Long-Term Investments 10.3m
PP&E 5.1m
Other Non-Current Assets 9.9m
Efficiency

Free Cash Flow Analysis
Innate Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Innate Pharma SA

Revenue
12.6m EUR
Operating Expenses
-64.2m EUR
Operating Income
-51.6m EUR
Other Expenses
2.1m EUR
Net Income
-49.5m EUR
Fundamental Scores

IPH Profitability Score
Profitability Due Diligence

Innate Pharma SA's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

Strong 3Y Average Gross Margin
Declining Net Margin
Low Gross Margin
Declining Operating Margin
13/100
Profitability
Score

Innate Pharma SA's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

IPH Solvency Score
Solvency Due Diligence

Innate Pharma SA's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
39/100
Solvency
Score

Innate Pharma SA's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 5.282 EUR with a low forecast of 2.515 EUR and a high forecast of 8.82 EUR.

Lowest
Price Target
2.515 EUR
71% Upside
Average
Price Target
5.282 EUR
258% Upside
Highest
Price Target
8.82 EUR
498% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Innate Pharma SA
does not pay dividends
Shareholder Yield

Current shareholder yield for IPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

IPH Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one IPH stock?

The intrinsic value of one IPH stock under the Base Case scenario is 4.719 EUR.

Is IPH stock undervalued or overvalued?

Compared to the current market price of 1.474 EUR, Innate Pharma SA is Undervalued by 69%.

Back to Top